lividomycin A

Details

• Internal ID: 37fd9380-58dd-4282-822f-ca359db47b59
• Taxonomy: Organic oxygen compounds > Organooxygen compounds > Carbohydrates and carbohydrate conjugates > 2-deoxystreptamine aminoglycosides > 4,5-disubstituted 2-deoxystreptamines
• IUPAC Name: (2R,3S,4S,5S,6R)-2-[(2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(2R,3S,4R,5S)-5-[(1R,2R,3S,5R,6S)-3,5-diamino-2-[(2S,3R,5S,6R)-3-amino-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxy-4-hydroxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
• SMILES (Canonical): C1C(C(C(C(C1N)OC2C(CC(C(O2)CO)O)N)OC3C(C(C(O3)CO)OC4C(C(C(C(O4)CN)OC5C(C(C(C(O5)CO)O)O)O)O)N)O)O)N
• SMILES (Isomeric): C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H](C[C@@H]([C@H](O2)CO)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O[C@@H]5[C@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O)N)O)O)N
• InChI: InChI=1S/C29H55N5O18/c30-3-11-23(51-28-20(43)19(42)17(40)13(5-36)47-28)18(41)15(34)27(45-11)50-24-14(6-37)48-29(21(24)44)52-25-16(39)7(31)1-8(32)22(25)49-26-9(33)2-10(38)12(4-35)46-26/h7-29,35-44H,1-6,30-34H2/t7-,8+,9-,10+,11+,12-,13-,14-,15-,16+,17-,18-,19+,20+,21-,22-,23-,24-,25-,26-,27-,28-,29+/m1/s1
• InChI Key: DBLVDAUGBTYDFR-SWMBIRFSSA-N
• Popularity: 151 references in papers

Physical and Chemical Properties

• Molecular Formula: C₂₉H₅₅N₅O₁₈
• Molecular Weight: 761.80 g/mol
• Exact Mass: 761.35420992 g/mol
• Topological Polar Surface Area (TPSA): 406.00 Ų
• XlogP: -9.90
• Atomic LogP (AlogP): -10.01
• H-Bond Acceptor: 23
• H-Bond Donor: 15
• Rotatable Bonds: 12

Synonyms

• Lividomycin
• Quintomycin B
• 36441-41-5
• Mannosyldeoxyparomomycin
• Antibiotic 503-2
• Antibiotic SF 767 A
• Lividomicina
• Lividomycine
• Lividomycinum
• SF 767 A
• CHEBI:71961
• 11111-23-2
• A606AJ494W
• (1R,2R,3S,4R,6S)-4,6-diamino-3-hydroxy-2-{[alpha-D-mannopyranosyl-(1->4)-2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl-(1->3)-beta-D-ribofuranosyl]oxy}cyclohexyl 2-amino-2,3-dideoxy-alpha-D-ribo-hexopyranoside
• O-2-Amino-2,3-dideoxy-alpha-D-ribo-hexopyranosyl-(1-4)-O-(O-alpha-D-mannopyranosyl-(1-4)-O-2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl-(1-3)-beta-D-ribofuranosyl-(1-5))-2-deoxy-D-streptamine
• LIV
• Livodymycin
• Lividomycin [INN:DCF]
• Lividomycine [INN-French]
• Lividomycinum [INN-Latin]
• Lividomicina [INN-Spanish]
• Lividomycin A sulfate salt
• BRN 6763509
• UNII-A606AJ494W
• (2R,3S,4S,5S,6R)-2-((2S,3S,4R,5R,6R)-5-AMINO-2-(AMINOMETHYL)-6-((2R,3S,4R,5S)-5-((1R,2R,3S,5R,6S)-3,5-DIAMINO-2-((2S,3R ,5S,6R)-3-AMINO-5-HYDROXY-6-(HYDROXYMETHYL)-TETRAHYDRO-2H-PYRAN-2-YLOXY)-6-HYDROXYCYCLOHEXYLOXY)-4-HYDROXY-2-(HYDROXYMET HYL)-TETRAHYDROFURAN-3-YLOXY)-4-HYDROXY-TETRAHYDRO-2H-PYRAN-3-YLOXY)-6-(HYDROXYMETHYL)-TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL
• LIVIDOMYCIN [INN]
• SCHEMBL195432
• CHEMBL389029
• DTXSID8023218
• BDBM50534265
• AKOS040752615
• DB04728
• (2R,3S,4S,5S,6R)-2-((2S,3S,4R,5R,6R)-5-AMINO-2-(AMINOMETHYL)-6-((2R,3S,4R,5S)-5-((1R,2R,3S,5R,6S)-3,5-DIAMINO-2-((2S,3R,5S,6R)-3-AMINO-5-HYDROXY-6-(HYDROXYMETHYL)-TETRAHYDRO-2H-PYRAN-2-YLOXY)-6-HYDROXYCYCLOHEXYLOXY)-4-HYDROXY-2-(HYDROXYMETHYL)-TETRAHYDROFURAN-3-YLOXY)-4-HYDROXY-TETRAHYDRO-2H-PYRAN-3-YLOXY)-6-(HYDROXYMETHYL)-TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL
• (2R,3S,4S,5S,6R)-2-[(2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(2R,3S,4R,5S)-5-[(1R,2R,3S,5R,6S)-3,5-diamino-2-[(2S,3R,5S,6R)-3-amino-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxy-4-hydroxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
• D-Streptamine, O-2-amino-2,3-dideoxy-alpha-D-ribo-hexopyranosyl-(1-4)-O- (O-alpha-D-mannopyranosyl-(1-4)-O-2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl-(1-3)-beta-D-ribofuranosyl-(1-5))-2-deoxy-
• O-2-Amino-2,3-dideoxy-alpha-D-ribo-hexopyranosyl-(1->4)-O-(O-alpha-D-mannopyranosyl-(1->4)-O-2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl-(1->3)-beta-D-ribofuranosyl-(1->5))-2-deoxy-D-streptamine
• C17707
• Q6658885
• (2R,3S,4S,5S,6R)-2-(((2S,3S,4R,5R,6R)-5-Amino-2-(aminomethyl)-6-(((2R,3S,4R,5S)-5-(((1R,2R,3S,5R,6S)-3,5-diamino-2-(((2S,3R,5S,6R)-3-amino-5-hydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-6-hydroxycyclohexyl)oxy)-4-hydroxy-2-(hydroxymethyl)tetrahy
• (2R,3S,4S,5S,6R)-2-((2S,3S,4R,5R,6R)-5-AMINO-2-(AMINOMETHYL)-6-((2R,3S,4R,5S)-5-((1R,2R,3S,5R,6S)-3,5-DIAMINO-2-((2S,3R
• (2R,3S,4S,5S,6R)-2-[(2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(2R,3S,4R,5S)-5-[(1R,2R,3S,5R,6S)-3,5-diamino-2-[(2S,3R,5S,6R)-3-amino-5-hydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-6-hydroxy-cyclohexoxy]-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-yl]oxy-4-hydroxy-tetrahydropyran-3-yl]oxy-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol
• ,5S,6R)-3-AMINO-5-HYDROXY-6-(HYDROXYMETHYL)-TETRAHYDRO-2H-PYRAN-2-YLOXY)-6-HYDROXYCYCLOHEXYLOXY)-4-HYDROXY-2-(HYDROXYMET
• D-Streptamine, O-alpha-D-mannopyranosyl-(1-->4)-O-2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl-(1-->3)-O-beta-D-ribofuranosyl-(1-->5)-O-[2-amino-2,3-dideoxy-alpha-D-ribo-hexopyranosyl-(1-->4)]-2-deoxy-
• HYL)-TETRAHYDROFURAN-3-YLOXY)-4-HYDROXY-TETRAHYDRO-2H-PYRAN-3-YLOXY)-6-(HYDROXYMETHYL)-TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL
• O-2-AMINO-2,3-DIDEOXY-.ALPHA.-D-RIBO-HEXOPYRANOSYL-(1->4)-O-(O-.ALPHA.-D-MANNOPYRANOSYL-(1->4)-O-2,6-DIAMINO-2,6-DIDEOXY-.BETA.-L-IDOPYRANOSYL-(1->3)-.BETA.-D-RIBOFURANOSYL-(1->5))-2-DEOXY-D-STREPTAMINE

2D Structure

ADMET Properties (via admetSAR 2)

Target	Value	Probability (raw)	Probability (%)
Human Intestinal Absorption	-	0.9679	96.79%
Caco-2	-	0.8750	87.50%
Blood Brain Barrier	-	0.9250	92.50%
Human oral bioavailability	-	0.9857	98.57%
Subcellular localzation	Lysosomes	0.4808	48.08%
OATP2B1 inhibitior	-	1.0000	100.00%
OATP1B1 inhibitior	+	0.9136	91.36%
OATP1B3 inhibitior	+	0.9497	94.97%
MATE1 inhibitior	-	0.9800	98.00%
OCT2 inhibitior	-	0.7500	75.00%
BSEP inhibitior	-	0.8069	80.69%
P-glycoprotein inhibitior	-	0.5355	53.55%
P-glycoprotein substrate	-	0.8085	80.85%
CYP3A4 substrate	+	0.6045	60.45%
CYP2C9 substrate	-	1.0000	100.00%
CYP2D6 substrate	-	0.7688	76.88%
CYP3A4 inhibition	-	0.9583	95.83%
CYP2C9 inhibition	-	0.9252	92.52%
CYP2C19 inhibition	-	0.9012	90.12%
CYP2D6 inhibition	-	0.9171	91.71%
CYP1A2 inhibition	-	0.9094	90.94%
CYP2C8 inhibition	-	0.5716	57.16%
CYP inhibitory promiscuity	-	0.8716	87.16%
UGT catelyzed	+	0.8000	80.00%
Carcinogenicity (binary)	-	1.0000	100.00%
Carcinogenicity (trinary)	Non-required	0.6341	63.41%
Eye corrosion	-	0.9872	98.72%
Eye irritation	-	0.9079	90.79%
Skin irritation	-	0.7882	78.82%
Skin corrosion	-	0.9128	91.28%
Ames mutagenesis	-	0.7054	70.54%
Human Ether-a-go-go-Related Gene inhibition	+	0.7705	77.05%
Micronuclear	+	0.7600	76.00%
Hepatotoxicity	-	0.6663	66.63%
skin sensitisation	-	0.9394	93.94%
Respiratory toxicity	+	0.7333	73.33%
Reproductive toxicity	+	1.0000	100.00%
Mitochondrial toxicity	+	0.9125	91.25%
Nephrotoxicity	-	0.8208	82.08%
Acute Oral Toxicity (c)	IV	0.5746	57.46%
Estrogen receptor binding	+	0.6854	68.54%
Androgen receptor binding	-	0.6098	60.98%
Thyroid receptor binding	-	0.5000	50.00%
Glucocorticoid receptor binding	+	0.5758	57.58%
Aromatase binding	+	0.5776	57.76%
PPAR gamma	+	0.6673	66.73%
Honey bee toxicity	-	0.5882	58.82%
Biodegradation	-	0.7000	70.00%
Crustacea aquatic toxicity	-	0.5800	58.00%
Fish aquatic toxicity	-	0.9258	92.58%

Targets

Proven Targets:

No proven targets yet!

Predicted Targets (via Super-PRED):

CHEMBL ID	UniProt ID	Name	Probability	Model accuracy
CHEMBL3137262	O60341	LSD1/CoREST complex	97.56%	97.09%
CHEMBL5619	P27695	DNA-(apurinic or apyrimidinic site) lyase	97.18%	91.11%
CHEMBL3251	P19838	Nuclear factor NF-kappa-B p105 subunit	93.63%	96.09%
CHEMBL6136	O60341	Lysine-specific histone demethylase 1	91.64%	95.58%
CHEMBL226	P30542	Adenosine A1 receptor	89.47%	95.93%
CHEMBL3589	P55263	Adenosine kinase	89.38%	98.05%
CHEMBL5608	Q16288	NT-3 growth factor receptor	85.48%	95.89%
CHEMBL4187	Q99250	Sodium channel protein type II alpha subunit	82.79%	95.50%
CHEMBL2996	Q05655	Protein kinase C delta	81.66%	97.79%

Plants that contains it

There are no matching plants.

Cross-Links

• PubChem: 72394
• LOTUS: LTS0142316
• wikiData: Q6658885